Quantitative analysis for the cannabis cannabinoids such as cannabidiol and Δ-tetrahydrocannabinol in commercial products is necessary for evaluating label information, and assessing dosages and exposures when the products are consumed. Herein is presented a broadly applicable HPLC-DAD method for the determination of cannabis cannabinoids in commercial consumer products and traditional plant-related substances. The current method provides chromatographic resolution of 11 cannabinoids using a commercial, mixed C18-aromatic functionality stationary phase. The method uses 95% or pure ethanol for extraction, and certain modifications which address specific matrix types are detailed herein. Extensive method validation including precision and accuracy was conducted for five cannabinoids of primary interest (CBD, Δ-THC, CBDA, THCA, and CBN). UV detection provided excellent sensitivity with limits of quantitation (LOQs) of 10μg/g across cannabinoids. The method was applied to about 60 commercial products representing diverse product types and a broad range of cannabinoids amounts (0.01-350mg/g).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.forsciint.2018.05.033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: We present Phase 1 trial data using the Neuropsychiatric Inventory ("NPI") domains, NPI-delusions and NPI-hallucinations as symptoms of psychosis in participants with Alzheimer's ("AD") receiving IGC-AD1, a combination of low concentration delta 9-tetrahydrocannabinol ("THC") and melatonin. Cannabis use is considered an established risk factor for psychosis in young people. Psychosis is prevalent in AD patients, with around 50% experiencing it, generating safety concerns regarding the use of THC in these patients.
View Article and Find Full Text PDFBackground: Cannabis-based therapies have gained interest in treating different ailments in the elderly population, including severe or chronic pain, sleep disturbances, and more recently Alzheimer's Disease. This raises the importance of understanding the influence of age on the pharmacokinetics ("PK") of delta-9 tetrahydrocannabinol ("THC"). IGC-AD1 comprises THC at a low concentration and melatonin.
View Article and Find Full Text PDFThe Index of Cannabis Equivalence (ICE): A User-Centered Approach to Standardization of Cannabis Dose-Response.
J Psychoactive Drugs
January 2025
Department of Psychology, The University of British Columbia, Kelowna, BC, Canada.
The increasing acceptance of cannabis use, and policy changes in several jurisdictions has led researchers and public health experts to call for a standard cannabis dose. Standard dosing units are useful tools for regulation, substance use guidelines, data collection, consistency of research, as a means of communicating low-risk recommendations and dose-related effects, and for self-monitoring. Efforts to standardize cannabis dose have focused on cannabinoid content without considering tolerance or mode.
View Article and Find Full Text PDFPotential Risks from Cannabis-Infused Beverages: A Critical Review.
Cannabis
December 2024
Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton and McMaster University.
Unlabelled: Although Canada legalized cannabis beverages in 2019, most available research on acute cannabis intoxication derives from dried flower and edible products. The distinct bioavailability and pharmacokinetic properties of phytocannabinoids ingested from beverages, however, contribute to significantly different acute and long-term effects that need to be better understood to ensure consumer safety.
Objective: This review investigates existing cannabis beverage literature, with a particular focus on acute intoxication effects.
Perceived Risk of Medical Cannabis and Prescribed Cannabinoids for Chronic Pain: A Cross-Sectional Study Among Quebec Clinicians.
Cannabis
December 2024
Département des sciences de la santé, Université du Québec en Abitibi-Témiscamingue (UQAT).
Objective: An increase in medical cannabis and prescribed cannabinoids use for chronic pain management has been observed in Canada in the past years. This study aimed to: 1) Describe clinicians' perceived risk associated with the use of medical cannabis and prescribed cannabinoids for the management of chronic pain; and 2) Identify sociodemographic and professional factors associated with perceived risk of adverse effects.
Method: A web-based cross-sectional study was conducted in Quebec, Canada in 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!